New hope for lymphoma patients: mosunetuzumab under review

NCT ID NCT07278921

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks back at medical records of 25 adults with follicular lymphoma that returned or didn't respond to at least two prior treatments. All patients received mosunetuzumab through a compassionate use program. Researchers want to see how well the drug works and what side effects occur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

mosunetuzumab

What this could lead to

If successful, this could provide a treatment option for patients with follicular lymphoma who have not responded to other therapies.

What could go wrong

This is a small, retrospective observational study, not a controlled trial. Results may not apply to all patients, and there are risks like infusion reactions and nervous system side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • IRCCS Ospedale San Raffaele

    RECRUITING

    Milan, 20132, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••